TY - JOUR T1 - Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. AU - Dastghaib,L, AU - Azizzadeh,M, AU - Jafari,P, PY - 2005/5/18/pubmed PY - 2005/6/10/medline PY - 2005/5/18/entrez SP - 43 EP - 6 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 16 IS - 1 N2 - BACKGROUND: Tinea capitis is a relatively common fungal infection of childhood. Griseofulvin has been the mainstay of treatment for many years. However, newer oral antifungal agents are being used more frequently. OBJECTIVE: Our purpose was to evaluate the therapeutic efficacy of fluconazole in comparison with griseofulvin in the treatment of tinea capitis. METHODS: We performed a single-blind, randomized, prospective evaluation of 40 patients with a clinical and mycologic diagnosis of tinea capitis. One group received fluconazole for 4 weeks. The other group received griseofulvin for 6 weeks. Five clinical parameters were evaluated. Mycologic examinations were performed at baseline and at the end of 8 weeks. RESULTS: Patients ranged in age from 1 to 16 years; 80% were boys and 20% were girls. Mycologic examinations disclosed Trichophyton verrucosum in 40% of patients, T. violaceum in 40% and Microsporum canis in 20%. At week 8, the griseofulvin-treated group showed a cure rate of 76%, and the fluconazole-treated group 78%. The cure rates were not statistically significant. CONCLUSION: Fluconazole constitutes an alternative but, because of greater availability and lower cost, griseofulvin remains the treatment of choice for tinea capitis. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/15897167/Therapeutic_options_for_the_treatment_of_tinea_capitis:_griseofulvin_versus_fluconazole_ L2 - https://www.tandfonline.com/doi/full/10.1080/09546630510025932 DB - PRIME DP - Unbound Medicine ER -